Bifogade filer
Prenumeration
Kalender
Est. tid* | ||
2026-02-20 | 07:30 | Bokslutskommuniké 2025 |
2025-11-07 | 07:30 | Kvartalsrapport 2025-Q3 |
2025-08-21 | 07:30 | Kvartalsrapport 2025-Q2 |
2025-06-18 | N/A | Årsstämma |
2025-05-30 | 07:30 | Kvartalsrapport 2025-Q1 |
2025-05-28 | N/A | X-dag ordinarie utdelning PLUN 0.00 SEK |
2025-02-20 | - | Bokslutskommuniké 2024 |
2024-12-23 | - | Split PLUN 40:1 |
2024-12-05 | - | Extra Bolagsstämma 2024 |
2024-11-07 | - | Kvartalsrapport 2024-Q3 |
2024-08-19 | - | Kvartalsrapport 2024-Q2 |
2024-05-31 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2024-05-30 | - | Årsstämma |
2024-05-16 | - | Kvartalsrapport 2024-Q1 |
2024-02-16 | - | Bokslutskommuniké 2023 |
2023-11-07 | - | Kvartalsrapport 2023-Q3 |
2023-10-12 | - | Extra Bolagsstämma 2023 |
2023-07-14 | - | Kvartalsrapport 2023-Q2 |
2023-05-17 | - | Kvartalsrapport 2023-Q1 |
2023-05-05 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2023-05-04 | - | Årsstämma |
2023-02-15 | - | Bokslutskommuniké 2022 |
2022-10-21 | - | Kvartalsrapport 2022-Q3 |
2022-07-14 | - | Kvartalsrapport 2022-Q2 |
2022-05-06 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2022-05-05 | - | Årsstämma |
2022-05-05 | - | Kvartalsrapport 2022-Q1 |
2022-02-18 | - | Bokslutskommuniké 2021 |
2021-10-22 | - | Kvartalsrapport 2021-Q3 |
2021-08-19 | - | Kvartalsrapport 2021-Q2 |
2021-05-12 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2021-05-11 | - | Årsstämma |
2021-05-07 | - | Kvartalsrapport 2021-Q1 |
2021-02-19 | - | Bokslutskommuniké 2020 |
2020-10-23 | - | Kvartalsrapport 2020-Q3 |
2020-08-21 | - | Kvartalsrapport 2020-Q2 |
2020-05-08 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2020-05-07 | - | Årsstämma |
2020-05-07 | - | Kvartalsrapport 2020-Q1 |
2020-02-13 | - | Bokslutskommuniké 2019 |
2019-10-24 | - | Kvartalsrapport 2019-Q3 |
2019-08-21 | - | Kvartalsrapport 2019-Q2 |
2019-05-17 | - | Årsstämma |
2019-05-08 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2019-04-16 | - | Årsstämma |
2019-04-16 | - | Kvartalsrapport 2019-Q1 |
2019-02-22 | - | Bokslutskommuniké 2018 |
2018-11-14 | - | Kvartalsrapport 2018-Q3 |
2018-08-21 | - | Kvartalsrapport 2018-Q2 |
2018-05-17 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2018-05-16 | - | Årsstämma |
2018-05-16 | - | Kvartalsrapport 2018-Q1 |
2018-02-28 | - | Bokslutskommuniké 2017 |
2017-11-16 | - | Kvartalsrapport 2017-Q3 |
2017-08-24 | - | Kvartalsrapport 2017-Q2 |
2017-05-10 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2017-05-09 | - | Årsstämma |
2017-05-09 | - | Kvartalsrapport 2017-Q1 |
2017-02-23 | - | Bokslutskommuniké 2016 |
2016-11-10 | - | Kvartalsrapport 2016-Q3 |
2016-08-25 | - | Kvartalsrapport 2016-Q2 |
2016-05-18 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2016-05-17 | - | Årsstämma |
2016-05-17 | - | Kvartalsrapport 2016-Q1 |
2016-02-26 | - | Bokslutskommuniké 2015 |
2015-11-13 | - | Kvartalsrapport 2015-Q3 |
2015-08-28 | - | Kvartalsrapport 2015-Q2 |
2015-05-12 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2015-05-11 | - | Årsstämma |
2015-05-11 | - | Kvartalsrapport 2015-Q1 |
2015-02-27 | - | Bokslutskommuniké 2014 |
2014-11-28 | - | Kvartalsrapport 2014-Q3 |
2014-08-29 | - | Kvartalsrapport 2014-Q2 |
2014-05-14 | - | Kvartalsrapport 2014-Q1 |
2014-05-06 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2014-05-05 | - | Årsstämma |
2014-02-22 | - | Bokslutskommuniké 2013 |
2013-11-20 | - | Kvartalsrapport 2013-Q3 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
The first patients with benign prostatic hyperplasia have been successfully treated using our new CoreTherm® Eagle platform.
“We are very pleased that the first patients have been successfully treated with our new CoreTherm® Eagle platform. This is an important milestone for us and a clear result of the focused work carried out internally. With CoreTherm® Eagle, the opportunity opens up to offer more clinics, both in the Nordic region and globally, an effective treatment method,” says Johan Lavén, Sales and Marketing Director at ProstaLund.
CoreTherm® Eagle builds on the proven and well-established technology that has been developed and refined over 25 years in earlier CoreTherm® platforms, used in over 30,000 treatments for benign prostatic hyperplasia in the Nordics. The new CoreTherm® Eagle has undergone significant technical and component upgrades. Among other things, the calculation of recommended treatment goals has been automated and integrated into the new platform. This provides increased support for the user and further enhances ease of use.
For further information, please contact:
Johan Lavén, Sales and Marketing Director
Telefon: +46 (0) 73 330 92 16
E-post: johan.laven@prostalund.com
About CoreTherm®
About ProstaLund
Certified Adviser
Västra Hamnen Corporate Finance AB
Phone: +46 (0) 40 200 250
Email: ca@vhcorp.se
About CoreTherm®
CoreTherm® is a minimally invasive transurethral microwave thermotherapy for benign prostatic enlargement (BPH). The treatment is performed in an outpatient setting under local anaesthesia and takes less than 15 minutes. No general anaesthesia or spinal block is needed. Follow-up data five years after CoreTherm® treatment shows clinical outcomes comparable to those seen after surgery/TURP (transurethral resection of the prostate), but with lower risk of serious complications. For more information visit, www.coretherm.com.
About ProstaLund
ProstaLund AB (publ) is a Swedish medtech company headquartered in Lund that develops and markets innovative products for the treatment of Benign Prostatic Enlargement (BPH). The company has patented the CoreTherm® Concept, a customised thermal treatment for BPE. ProstaLund is listed on Nasdaq First North Growth Market and has approximately 3,500 shareholders. For more information, visit www.prostalund.se. Our press releases are also available to read and download here: www.prostalund.se/pressmeddelanden
Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se